Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
NCT00240019
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Diabetic Nephropathy
Interventions
DRUG:
Addition of furosemide 20 mg oral bid to baseline regimen
Sponsor
Stanford University
Collaborators
[object Object]